Relapsed Adult AML Clinical Trial
Official title:
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Patients with newly diagnosed AML confront a sudden and life-threatening diagnosis, requiring an immediate disruption of their life and an urgent hospitalization to begin therapy. During their hospitalization for chemotherapy, patients with AML often experience difficult physical symptoms that negatively impact their quality of life and physical function. Patients with AML also experience significant psychological distress as they combat the abrupt onset of illness, uncertainty regarding their prognosis, physical and social isolation during hospitalization, and complete loss of independence. The abrupt onset of these symptoms can be distressing to both the patient and their family and friends (also called "caregivers"). Research has shown that early involvement of a team of clinicians specializing in lessening (or "palliating") these physical and emotional symptoms and helping patients and their caregivers cope with AML improves their quality of life and experience with their illness. This team is called "specialty palliative care" and consists of physicians and advanced practice providers who work closely and collaboratively with the oncology team to care for patients and caregivers. Research has also shown that training oncology clinicians to incorporate palliative care skills into their practice, called "primary palliative care," is an alternative strategy to having specialty palliative care clinicians care for patients with leukemia. The purpose of this study is to determine whether specialty palliative care or primary palliative care is the best way to improve the quality of life and experience of patients with AML and their caregivers. This study will randomly assign hospitals to deliver either specialty palliative care or primary palliative care for patients with AML. Participants in this study will receive either specialty or primary palliative care during their hospital stays based upon which strategy their hospital has been assigned to. Participants assigned to specialty palliative care will be care for by both oncology and palliative care clinicians during their hospital stays for AML. Participants assigned to primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during their hospital stays for AML. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06141304 -
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
|
Phase 2 | |
| Active, not recruiting |
NCT05029141 -
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT03848754 -
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Not yet recruiting |
NCT06007911 -
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT04722952 -
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
|
Phase 3 | |
| Withdrawn |
NCT03932318 -
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06307054 -
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
|
Phase 1 | |
| Recruiting |
NCT04310592 -
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
|
Phase 1 | |
| Active, not recruiting |
NCT04139434 -
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
|
Phase 1 | |
| Completed |
NCT05193448 -
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
|
||
| Recruiting |
NCT03867682 -
Venetoclax and Lintuzumab-Ac225 in AML Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06022003 -
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04330820 -
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05305859 -
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
|
Phase 2 | |
| Approved for marketing |
NCT03245424 -
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
|